Farmas USA

a mi el toro me ha dejado más de una vez como al de la foto.

pues está atento a tu precio de momento máximo 0.655 es el precio de la vela de cierre verde del 9 de abril, espero equivocarme pero si antes de apertura no supera esos valores y viendo el mercado será donde ponerse corto para sacarle unos duros, mira ejemplo baxs del otro día. puedo estar equivocado es una reflexión en voz alta.

ibb

parado en el precio apertura del viernes y por debajo justo de la media de 200 sesiones.

Arena en la TV

Arena Pharmaceuticals Reports Eisai's Launch of National Television Advertising Campaign for BELVIQ(R) (lorcaserin HCl) CIV for Chronic Weight Management

SAN DIEGO, April 14, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai Inc. has launched a national television advertising campaign for BELVIQ® (lorcaserin HCl), an FDA-approved prescription treatment for chronic weight management. The initial advertisement, which illustrates the struggles that many people face with hunger and body weight, will air on Lifetime, Oxygen, AMC and numerous other networks. BELVIQ is presented as a targeted approach to weight loss, that, when combined with diet and increased activity, may help patients lose weight and keep it off.

"Eisai continues to ramp up its sales and marketing initiatives for BELVIQ as planned," said Jack Lief, Arena's President and Chief Executive Officer. "This expanded outreach to consumers is designed to raise awareness about the availability of BELVIQ as a treatment option and encourage a productive dialogue between patients and physicians about the health benefits of weight loss and whether BELVIQ is right for them as part of a chronic weight management program."

The television advertising campaign builds upon the national print advertising campaign Eisai launched in October 2013. The television advertisement is intended to encourage patients to talk to their doctor about BELVIQ, including a free 15-day offer for the treatment, and direct them to visit www.StartBELVIQnow.com or call 800.934.2096 to obtain additional information. Once a patient obtains a prescription for BELVIQ, he or she is eligible for BELIEVE EVERYDAY SUPPORTSM, a customizable online program that provides support and savings for patients.

To view the television advertisement and additional multimedia content associated with this announcement, please click here.

BELVIQ is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related, comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes). It is not known if BELVIQ is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products, and the effect of BELVIQ on cardiovascular morbidity and mortality has not been established.

MSTX

Totalmente de acuerdo, viendo como se movía antes del anuncio de la dilución ATM un 16% de subida en pre se antoja poco. Con el mercado en plan caótico es lógico pensar que el colocador aproveche estos tirones para empapelar al personal y continuar con la ATM. Buscar los máximos del día y ponerse corto puede dar un 10% fácil hoy.

SNTA

Colocación de acciones 1.250.000 a 4,01

http://www.streetinsider.com/Equity+Offerings/Synta+Pharma+%28SNTA%29+Enters+1.25M+Common+Sales+Agreement+at+%244.01Share/9376468.html?si_client=intbro

crece la demanda minorista.

http://www.briefing.com/investor/analysis/story-stocks/solid-retail-sales-report-highlights-steady-demand-growth.htm

mstx

por aquí sería el corto, si rompe 0.67 se va arriba aunque el rsi está alto y mucha venta en 0.67

CVM

Dilución. $10M (a 1,40)
Eramos pocos y parió la abuela...
S2
http://www.heraldonline.com/2014/04/14/5867222/cel-sci-corporation-prices-10.html?sp=/100/773/385/